On December 17, 2025, South San Francisco-based Sutro Biopharma, Inc. revealed that it has met the Nasdaq Stock Market's requirement for a minimum share price under Rule 5450(a)(1). The company, traded under NASDAQ: STRO, specializes in creating site-specific and innovative antibody drug conjugates for oncology treatment. This news indicates that Sutro has satisfied Nasdaq's listing standard, ensuring its continued presence on the stock market.